Title

Expression in Aromatase Inhibitor Responder vs. Non-Responder HR+ Breast Cancer Cohorts

Authors

Jeffrey Hayashi
Tomoko Yamazaki
Venkatesh Rajamanickam
Joanna Pucilowska
Christopher Dubay
David Page
Kristina Young

Date

Fall 2018

Faculty Advisor

Kristina Young

Sponsor

Providence Cancer Center, Earle A. Chiles Research Institute, University of Portland, The Oregon Clinic

College/School

College of Arts & Sciences

Department

Department of Biology

Abstract

Hormone receptor positive (HR+) breast cancer patients have an excellent prognosis with over 85% cure rates. However, 20,000 women with HR+ breast cancer die annually from tumor recurrence. Those at highest risk for recurrence are those women whose tumors continue to proliferate through estrogen blockade (Figure 4). Addition of chemotherapy for these patients failed to improve outcomes. We retrospectively identified women with HR+ breast cancer treated neoadjuvantly with aromatase inhibitors (AI), and selected matched patient cohorts for responders and non-responders determined by post-AI Ki67 of

Subjects

Breast--Cancer--Research; Breast--Cancer--Treatment; Oncology

Publication Information

A Summer Research Celebration Project

© 2018 The Authors

Citation: Pilot Scholars Version (Modified MLA Style)

Hayashi, Jeffrey; Yamazaki, Tomoko; Rajamanickam, Venkatesh; Pucilowska, Joanna; Dubay, Christopher; Page, David; and Young, Kristina, "Expression in Aromatase Inhibitor Responder vs. Non-Responder HR+ Breast Cancer Cohorts" (2018). Biology Undergraduate Publications, Presentations and Projects. 10.
https://pilotscholars.up.edu/bio_studpubs/10

Document Type

Student Project